Anti-TRIM21 is independently associated with mortality in patients with SSc.Anti-TRIM21 positivity is an independent risk factor for the development of PAH and mortality but does not demonstrate any association with ILD or other surrogate measures of lung function in a large Australian cohort of SSc patients. Here, TRIM21 is linked to interstitial lung disease.